Enfin disponible en Europe, grâce à une étonnante formule Europe, 100% naturelle, vous pouvez maintenant dire stop à vos problèmes d’impuissance et à vos troubles de la virilité. Cette formule révolutionnaire agit comme un véritable achat cialis naturel. Ses résultats sont immédiats, sans aucun effet secondaire et vos érections sont durables, quelque soit votre âge. Même si vous avez plus de 50 ans !

Phs 398 (rev. 9/04), biographical sketch format page

BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors. Follow this format for each person. DO NOT EXCEED FOUR PAGES.
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such University of Western Ontario, London ON A. Positions and Honors.

Positions and Employment

1989-1991
Head, Clinical Trials & Epidemiology, Sunnybrook Health Sciences Centre, Toronto ON Professor, Clinical Epidemiology and Biostatistics, McMaster University, Hamilton ON 2002-present Senior Scientist, CHES, SickKids Research Institute, Toronto ON
2002-present Professor, Dalla Lana School of Public Health, University of Toronto, Toronto ON

Honors
1977-1979
Best Paper Award from the Society for Medical Decision Making, co-author Research Award for Methodology Excellence, ISPOR, primary author Research Award for Methodology Excellence, ISPOR, co-author Research Award for Methodology Excellence, ISPOR, co- author B. Selected peer-reviewed publications (in chronological order).
(Publications selected from 237 peer-reviewed publications) Willan A, Watts D. Meaningful multicollinearity measures. Technometrics 1978; 20:407-412.
Willan A. Relative efficiency in survival analysis. J Chron Dis 1983; 36:183-192.
Pater J, Willan A. Clinical trials as diagnostic tests. Control Clin Trials 1984; 5:107-113.
Pater J, Willan A. Methodologic issues in trials of antiemetics. J Clin Oncol 1984; 2:484-487.
Willan A, Pater J. Hypothesis testing and sample size for bivariate binomial response in the comparison
of two groups. J Chron Dis 1985; 38:603-608.
Willan A, Pater J. Carryover and the two-period crossover clinical trial. Biometrics 1986; 42:593-599.
Willan A, Pater J. Using baseline measurements in the two period crossover clinical trial. Control Clin
Trials
1986; 7:282-289.
Burnett R, Willan A. Linear rank tests for randomized block designs. Communications in Statistics A
1988; 17:2455-2470.
Willan A. Using the maximum test statistic in the two period crossover clinical trial. Biometrics 1988;
44
:211-218.
Willan A, MacKenzie T. The severity of illness and laboratory testing. Can J Public Health 1988;
79
:435-439.
Willan A, Ross W, MacKenzie T. A comparison of in-patient classification systems: A problem on non-
nested regressions. Stat Med 1992; 11:1321-1331.
Willan A. Power function arguments in support of an alternative approach for analyzing management
trials. Control Clin Trials 1994; 15:211-219.
Willan A, Cruess AF, Ballantyne M. Argon green vs krypton red laser photocoagulation of extrafoveal
choroidal Neovascular Lesions: Three-year results in age-related macular generation. Can J Ophthalmol
1996; 31:11-17.
Willan A, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: An application of Fieller's
Theorem. Health Economics 1996; 5:297-305. Addendum 1999; 8(4).
Cook RJ, Willan A. Design considerations in crossover trials with a single interim analysis and serial
patient entry. Biometrics 1996; 52:732-739.
Willan A, O'Brien BJ, Cook DJ. Benefit-risk ratios in the assessment of the clinical evidence of a new
therapy. Control Clin Trials 1997; 18:121-130.
Willan AR, O’Brien BJ. Sample size and power issues in estimating incremental cost-effectiveness
ratios from clinical trials data. Health Economics 1999; 8:203-211.
Willan AR, Lin DY. Incremental net benefit in randomized clinical trials. Stat Med. 2001; 20:1563-1574.
PA
Willan AR, Analysis, sample size and power for estimating incremental net health benefit from clinical
trial data. Control Clin Trials. 2001; 22:228-237.
Willan AR, O'Brien BJ. Cost prediction models for the comparison of two groups. Health Economics
2001; 10:363-366.
Willan AR, O’Brien BJ, Leyva RA. Cost-effectiveness analysis when the WTA is greater than the WTP.
Stat Med 2001; 20:3251-3259.
Willan AR. On the probability of cost-effectiveness using data from randomized clinical trials. BMC
Med Res Meth
2001;1:8. ( www.biomedcentral.com/1471-2288/1/8/ )
Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue:
a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Economics
2002; 11:415-430.
Willan AR, Lin DY, Cook RJ, Chen E. Using inverse-weighing in cost-effectiveness analysis with
censored data. Statistical Methods in Medical Research 2002; 11:539-551.
Willan AR, Chen E, Cook RJ, Lin DY. Incremental net benefit in randomized clinical trials with
qualify-adjusted survival. Statistics in Medicine 2003; 22:353-362.
Willan AR. Incremental net benefit in the analysis of economic data from clinical trials with application
to the CADET-Hp Trial. European Journal of Gastroenterology and Hepatology 2004; 16:543-549.
Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis
for non-censored cost-effectiveness data. Health Economics 2004; 13:461-475.
Willan AR, Lin DY, Manca A. Regression methods for cost-effectiveness analysis with censored data.
Statistics in Medicine 2005; 24:131-145.
Willan AR, Pinto EM, O’Brien BJ, Kaul P, Goeree R, Lynd L, Armstrong PW. Country specific cost
comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the
Canadian ASSENT-3 economic analysis. Health Economics 2005; 14:327-328.
Willan AR, Pinto EM. The expected value of information and optimal clinical trial design. Statistics in
Medicine
2005; 24:1791-1806.
Pinto EM, Willan AR, O’Brien BJ. Cost-effectiveness analysis for multinational clinical trials. Statistics
in Medicine
2005; 24:1965-1982.
Willan AR, Goeree, R, Pinto EM, McBurney C, Blackhouse G. Economic evaluation of rivastigmine in
patients with parkinson’s disease dementia. Pharmacoeconomics 2006; 24: 93-106.
Willan AR. Statistical analysis of cost-effectiveness data from randomized clinical trials. Expert Rev.
Phamacoeconomics Outcomes Res
. 2006; 6: 337-346.
Manca A, Willan AR. Lost in translation”: accounting for between country differences in the analysis of
multinational cost effectiveness data. Pharmacoeconomics 2006; 24: 1101-1119.
Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health
Economics
2007; 16: 195-209.
Pullenayegum EM, Willan AR. Semi-parametric regression models for cost-effectiveness analysis:
improving the efficiency of estimation from censored data. Statistics in Medicine 2007; 26:3274-3299.
Willan AR. Clinical decision making and the expected value of information. Clinical Trials 2007; 4(2):.
Hossain A, Willan AR. Approximate MLEs of the parameters of location-scale models under type II
censoring. Statistics 2007; 41(5): 385-394.
Eckermann S, Willan AR. Time and EVSI wait for no patient. Value in Health 2008; 11: 522-526.
Willan AR, Kowgier ME. Cost-effectiveness Analysis of a Multinational RCT with a Binary Measure of
Effectiveness and an Interacting Covariate. Health Economics 2008; 17:777-791.
Eckermann S, Willan AR. The option value of delay in health technology assessment. Medical Decision
Making
2008; 28:300-305.
Eckermann S, Briggs A, Willan AR. Health technology assessment in the cost-disutility plane. Medical
Decision Making
2008; 28:172-181
Willan AR, Kowgier ME. Determining optimal sample sizes for multi-stage randomized clinical trials
using value of information methods. Clinical Trials 2008; 5: 289-300.
Willan AR. Optimal sample size determinations from an industry perspective based on the expected
value of information. Clinical Trials 2008; 5:587-594.
Murphy KE, Hannah ME, Willan AR et al. Multiple courses of antenatal corticosteroids for preterm
birth study (MACS): a randomised controlled trial. Lancet 2008; 372:2143-2151. .
Eckermann S, Willan AR. Globally optimal trial design for local decision making. Health Economics
2009; 18:203-216.
Schuh S, Willan AR, Stephens D, Dick PT, Coates A. Can Montelukast Shorten Prednisolone Therapy in
Children with Mild to Moderate Acute Asthma? A Randomized Controlled Trial. Journal of Pediatrics
2009; 155:795-800.
Eckermann S, Coory M, Willan AR. Indirect comparison: relative risk fallacies and odds solution.
Journal of Clinical Epidemiology 2009; 62:1031-1036.
Willan AR, Eckermann S. Optimal clinical trial design using value of information methods with
imperfect implementation. Health Economics 2010 19:549-561.
Hossain A, Beyene J, Willan AR, Hu P. Approximate Likelihood ratio test for detecting differential
expression in microarray data. Computational Statistics and Data Analysis 2009; 53(10): 3685-3695.
Boutis K, Willan AR, Babyn P, Goeree R, Howard A. A Randomized Controlled Trial of Cast Versus
Splint In Children with Acceptably Angulated Wrist Fractures. Canadian Medical Association Journal
2010; 182(14):1507-1512.
Eckermann S, Coory M, Willan AR. Consistently estimating risk difference when translating evidence to
jurisdiction of interest. PharmacoEconomics. 2011; 29(2):87-96.
Eckermann S, Karnon J, Willan AR. The value of Value of Information: best informing research design
and prioritization using current methods. Pharmacoeconomics 2010; 28:699-709.
Willan AR. Sample size determination for cost-effectiveness trials. PharmacoEconomics 2011; 29(11):
933-949.
Eckermann S, Willan AR. Presenting and summarizing cost and effect evidence to best inform inference
and societal decision making when comparing multiple strategies. PharmacoEconomics 2011; 29(7):563-
577.
Pullenayegum EM, Willan AR. Marginal models for censored longitudinal cost data: appropriate
working variance matrices in inverse-probability-weighted GEEs can improve precision. International
Journal of Biostatistics
2011; 7(1), Article 14.
Willan AR, Eckermann S. Value of information and pricing new health interventions. PharmaEconomics
2012; 30(6): 447-459.
Willan AR, Eckermann S. Accounting for between-study variation in value of information methodology.
Health Economics 2012; 21(10):1183–1195.
Willan AR, Boutis K, Goeree R. Value of Information methods for planning and analyzing clinical
studies optimize decision making and research planning. Journal of Clinical Epidemiology 2012; 65(8):
870-876.
Hossain A, Willan AR, Beyene J. An improved method on Wilcoxon rank sum test for gene selection
from microarray experiments. Communications in Statistics 2013; 42(7):1563-1577.
Eckermann S, Willan AR. Optimal global VOI trials: better aligning manufacturer and decision maker
interests and enabling feasible risk sharing. PharmacoEconomics 2013; 31(5):393-401.
Hossain A, Willan AR, Beyene J. A flexible nonparametric approach to find candidate genes associated
to disease in microarray experiments. Journal of Bioinformatics and Computational Biology 2013;
11(2):1250021 (19 pages).
Chen MH, Willan AR. Determining optimal sample sizes for multistage adaptive randomized clinical
trials from an industry perspective using value of information methods. Clinical Trials 2013; 10(1):54–
62.
Barrett JFR, Hannah ME, Hutton EK, Willan AR et al. A randomized trial of planned cesarean or
vaginal delivery for twin pregnancy. NEJM 2013; 369(14):1295-1305.
Asztalos EV, Murphy KE, Willan AR et al. Multiple courses of antenatal corticosteroids for preterm
birth study outcomes in children at 5 years of age (MACS-5). JAMA Pediatr.
doi:10.1001/jamapediatrics.2013.2764. Published online October 14, 2013.
Chan KKW, Willan AR, Gupta M, Pullenayegum E. Underestimation of uncertainties in health utilities
derived from mapping algorithms involving health related quality of life measures: Statistical
explanations and potential remedies. Medical Decision Making (accepted for publication).
Chen MH, Willan AR. Value of information methods for assessing a new diagnostic test. Statistics in
Medicine
(accepted for publication).

C. Research Support
Ongoing Research Support

1.
Canadian Institutes of Health Research, The Twin Birth Study. Barrett J (Principal Investigator), Hannah
M, Willan A, Ross S, Hutton E, et al., $8,608,045, 2003-2014.
National Science and Engineering Council, Expected Value of Information and Optimal Trial Design.
Willan AR (Principal Investigator) $70,000, 2008-2013.
Canadian Institutes of Health Research, The Bedside Paediatric Early Warning System: a cluster
randomized trial of mortality and processes of care. Parshuram C (Principal Investigator), Willan AR, et
al
. $3,959,716, 2010-2014.
Canadian Institutes of Health Research, Sustainability of a multidimensional knowledge translation
intervention to improve paediatric pain practices and outcomes. Bonnie Stevens (Principal Investigator),
Willan AR
, et al. $998,061, 2011-2014.
Bill and Belinda Gates Foundation, Parathyroid-vitamin D axis dysregulation in early-onset infant stunting
in resource-poor settings. Dan Roth (Principal Investigator), Willan AR, et al. $1,999,993, 2012-2016.
Canadian Institutes of Health Research, Impact of Emergency Department Probiotic Treatment of
Pediatric Gastroenteritis: Randomized Controlled Trial. Stephen Freedman (Principal Investigator),
Willan AR
, et al. $2,231,300, 2013-2018.

Source: http://www.andywillan.com/images/arwillanNIHcv.pdf

winsportsschools.org.uk

Administration of Medicines Policy and Procedures 2012 – 2013 Administration of Medicines Policy Aim: To ensure safe storage and administration of medication to pupils and staff by the nurses, house and secretarial staff. Storage: All medications are kept in a locked cupboard in a room not normally accessible to pupils. The medicines that require refrigeration are kept

Untitled

Anterior Vitrectomy The art of visualizing the vitreous. BY SCOTT E. BURK, MD, PHD; ANDREA P. DA MATA , MD; ROBERT H. OSHER, MD; AND ROBERT J. CIONNI, MD Vitreous gel, transparent by design, is virtually the agent. On the contrary, eyes receiving intracameralinvisible under the operating microscope. triamcinolone have a quieter postoperative course versusFurthermore, it is partic

Copyright © 2010-2014 Online pdf catalog